Veeda Lifesciences and Agilent Launch Joint CRO Center of Excellence for GLP-1 and Complex Biologics Analytics

• Veeda Lifesciences, a leading independent CRO based in India, and Agilent Technologies have announced a strategic collaboration to establish a joint Center of Excellence (CoE) at Veeda’s biopharma facility in Bengaluru, focused on delivering regulatory-aligned analytical and bioanalytical workflows for global biopharma sponsors.

• The CoE will integrate Agilent’s high-performance mass spectrometry with Veeda’s established bioanalytical, clinical research, and regulatory capabilities to support end-to-end analytical characterization of GLP-1-based drugs, monoclonal antibodies, antibody-drug conjugates (ADCs), and other complex therapeutic proteins.

Veeda Lifesciences, a leading independent CRO offering clinical, preclinical, and bioanalytical services from India, and Agilent Technologies (NYSE: A) have announced the launch of a joint Center of Excellence at Veeda’s biopharma facility in Bengaluru. Announced on May 13, 2026, the collaboration is designed to deliver inspection-ready analytical data across early development, clinical, and manufacturing stages for global biopharma sponsors navigating increasingly complex regulatory expectations for next-generation therapies.

The CoE will operate as a scalable analytics and regulatory-readiness hub, combining Agilent’s high-performance mass spectrometry instrumentation with Veeda’s established capabilities in proteomics, glycoproteomics, and process-related impurity analysis. The platform is specifically designed to meet the growing analytical demands of GLP-1-based drug programs — where sensitivity, throughput, and data integrity are critical to regulatory confidence and program progression — as well as other complex modalities including monoclonal antibodies, ADCs, and therapeutic proteins.

For biopharma sponsors outsourcing analytical and bioanalytical work to Indian CRO providers, the model addresses a gap between instrument capability and regulatory readiness. Rather than requiring sponsors to bridge Agilent workflow development expertise with CRO operational infrastructure separately, the integrated CoE delivers both under a single, GxP-aligned environment. The structure is intended to support decision-making at every stage of the development lifecycle — from early characterization through clinical and manufacturing — without requiring sponsors to engage multiple vendors for analytical services.

The announcement reflects a broader strategic trend in the Indian CRO market, where leading providers are investing in high-end analytical infrastructure to position India as a globally credible destination for complex biopharma development work. Agilent, which generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide, brings validated workflow development expertise across the regulatory landscape; Veeda brings an established network of investigators, clinical research infrastructure, and quality systems aligned with FDA expectations.

“Biopharma companies today require analytical capabilities that are inspection-ready from the outset. By collaborating with Agilent, we are strengthening our ability to deliver integrated, regulatory-aligned analytical workflows that support faster decision-making and smoother progression from early development through clinical and manufacturing stages.”

Binoy Gardi, Group CEO and Managing Director, Veeda Lifesciences